SAR-441169 is under clinical development by Lead Pharma and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAR-441169’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SAR-441169 overview

SAR-441169 is under development for the treatment of autoimmune diseases including rheumatoid arthritis, psoriasis and inflammatory bowel disease. The drug candidate is administered by oral route. The program consists of drugs that act by targeting nuclear receptor retinoic acid receptor-related orphan receptor gamma (RORgamma).

Lead Pharma overview

Lead Pharma is a drug discovery company that develops, discovers, and commercializes innovative therapeutics against cancer and autoimmune diseases. The company offers products such as RORyT, ERRa, LXR, and New Target Development. Its lead product pipeline program RORyt regulates the production of pro-inflammatory protein and finds application in the therapeutic area of autoimmune diseases. The company also develops LXR. It has a collaboration with Sanofi. Lead Pharma is headquartered in Oss, the Netherlands.

For a complete picture of SAR-441169’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.